Hostname: page-component-745bb68f8f-s22k5 Total loading time: 0 Render date: 2025-02-06T10:50:54.108Z Has data issue: false hasContentIssue false
  • English
  • Français

The use of Prochlorperazine (Stemetil) in Chronic Psychotic Disorders

Published online by Cambridge University Press:  08 February 2018

John Denham
John Denham*
Affiliation:
Whitchurch Hospital, Cardiff
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Prochlorperazine, 1-[3-(3-chloro-10-phenothiazinyl)propyl]-4-methyl-piperazine dimaleate, a phenothiazine derivative related to chlorpromazine, was discovered in the Rhône Poulenc laboratories, and studied pharmacologically in 1956, by Ducrot and Koetschet, for its anti-emetic properties. Clinical trials, following this experimental evidence, suggested that, as well as possessing powerful anti-emetic properties, the drug was of considerable therapeutic value in migraine, Ménière's syndrome, and vertigo of other origins.

Type
Original Articles
Information
Journal of Mental Science , Volume 104 , Issue 437 , October 1958 , pp. 1190 - 1194
Copyright
Copyright © Royal College of Psychiatrists, 1958 

References

Ducrot, R., and Koetschet, P., “Anti-emetic properties of a new phenothiazine derivative 3-chloro-10-(3-N-methylpiperasinylpropyl)-phenothiasine (6140 R.P.)”, Commn. Int. Physiol., Congr., Brussels, 30 July–4 August, 1956.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.